Physician

Endocrinology

P R. Larsen, MD practices Endocrinology. He went to medical school at Columbia University College of Physicians & Surgeons. Columbia University College of Physicians & Surgeons is a top medical college. Columbia University College of Physicians & Surgeons has a rank of 8 in research and a 52 in primary care He has 1 awards "Elected Member". Larsen is a published doctor. He published 100 publications, including: 'Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone.'

Publications

---

• Decade in review-thyroid disease: The endocrinology of thyroid disease from 2005 to 2015.
• Bethesda Categorization of Thyroid Nodule Cytology & Prediction of Thyroid Cancer Type and Prognosis.
• N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial.
• Inflammation-inducible type 2 deiodinase expression in the leptomeninges, choroid plexus and at brain blood vessels in male rodents.
• Thyroid hormones and skeletal muscle-new insights and potential implications.
• Cardiac Expression of Human Type 2 Iodothyronine Deiodinase Increases Glucose Metabolism and Protects Against Doxorubicin-induced Cardiac Dysfunction in Male Mice.
• A standardized assessment of thyroid nodules in children confirms higher cancer prevalence than in adults.
• Thyroid nodule size and prediction of cancer.
• Thyroid Hormone Promotes Postnatal Rat Pancreatic ?-Cell Development and Glucose-Responsive Insulin Secretion Through MAFA.
• Catalysis leads to posttranslational inactivation of the type 1 deiodinase and alters its conformation.
• Type-2 Iodothyronine 5'Deiodinase (D2) in Skeletal Muscle of C57Bl/6 Mice. II. Evidence for a Role of D2 in the Hypermetabolism of Thyroid Hormone Receptor {alpha}-Def...
• Type-2 Iodothyronine 5'Deiodinase in Skeletal Muscle of C57Bl/6 Mice. I. Identity, Subcellular Localization, and Characterization.
• IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells.
• Physiological role and regulation of iodothyronine deiodinases: a 2011 update.
• The predictive value of the fine-needle aspiration diagnosis "suspicious for a follicular neoplasm, hurthle cell type" in patients with hashimoto thyroiditis.
• Type 2 iodothyronine deiodinase levels are higher in slow-twitch than fast-twitch mouse skeletal muscle and are increased in hypothyroidism.
• The FoxO3/type 2 deiodinase pathway is required for normal mouse myogenesis and muscle regeneration.
• Distribution of hypophysiotropic thyrotropin-releasing hormone (TRH)-synthesizing neurons in the hypothalamic paraventricular nucleus of the mouse.
• Substitution of serine for proline in the active center of type 2 iodothyronine deiodinase substantially alters its in vitro biochemical properties with dithiothreitol...
• Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism.
• Thyroid hormone activation in vascular smooth muscle cells is negatively regulated by glucocorticoid.
• Type 2 iodothyronine deiodinase in human skeletal muscle: new insights into its physiological role and regulation.
• The thyroid hormone-inactivating deiodinase functions as a homodimer.
• Lack of association between the type 2 deiodinase A/G polymorphism and hypertensive traits: the Framingham Heart Study.
• Hypoxia-inducible factor induces local thyroid hormone inactivation during hypoxic-ischemic disease in rats.
• Activation of thyroid hormone is transcriptionally regulated by epidermal growth factor in human placenta-derived JEG3 cells.
• Cardiovascular and metabolic issues in patients with thyroid dysfunction will be highlighted at the Fifth Anniversary of ATA Spring Meetings in March 2008.
• Long-term assessment of a multidisciplinary approach to thyroid nodule diagnostic evaluation.
• Sonic hedgehog-induced type 3 deiodinase blocks thyroid hormone action enhancing proliferation of normal and malignant keratinocytes.
• Mice with impaired extrathyroidal thyroxine to 3,5,3'-triiodothyronine conversion maintain normal serum 3,5,3'-triiodothyronine concentrations.
• The type 2 deiodinase (DIO2) A/G polymorphism is not associated with glycemic traits: the Framingham Heart Study.
• Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound consensus conference statement.
• Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
• Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography.
• Atypical expression of type 2 iodothyronine deiodinase in thyrotrophs explains the thyroxine-mediated pituitary thyrotropin feedback mechanism.
• Transforming growth factor-beta promotes inactivation of extracellular thyroid hormones via transcriptional stimulation of type 3 iodothyronine deiodinase.
• Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans.
• Cellular and structural biology of the deiodinases.
• The type 2 deiodinase A/G (Thr92Ala) polymorphism is associated with decreased enzyme velocity and increased insulin resistance in patients with type 2 diabetes mellitus.
• Type 1 iodothyronine deiodinase is a sensitive marker of peripheral thyroid status in the mouse.
• CARs and drugs: a risky combination.
• A novel cell type-specific mechanism for thyroid hormone-dependent negative regulation of the human type 1 deiodinase gene.
• Timing and magnitude of increases in levothyroxine requirements during pregnancy in women with hypothyroidism.
• Chronic cardiac-specific thyrotoxicosis increases myocardial beta-adrenergic responsiveness.
• Lipopolysaccharide induces type 2 iodothyronine deiodinase in the mediobasal hypothalamus: implications for the nonthyroidal illness syndrome.
• Endoplasmic reticulum-associated degradation of the human type 2 iodothyronine deiodinase (D2) is mediated via an association between mammalian UBC7 and the carboxyl r...
• The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure.
• Genetic and biological subgroups of low-stage follicular thyroid cancer.
• In vivo dimerization of types 1, 2, and 3 iodothyronine selenodeiodinases.
• Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium.
• Natural history of benign solid and cystic thyroid nodules.
• Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as a cause of low circulating free thyroxine levels.
• Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes.
• A 21-year-old woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase.
• The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression.
• High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
• Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases.
• The type 2 iodothyronine deiodinase is essential for adaptive thermogenesis in brown adipose tissue.
• The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line.
• Regional physiological adaptation of the central nervous system deiodinases to iodine deficiency.
• The human, but not rat, dio2 gene is stimulated by thyroid transcription factor-1 (TTF-1).
• Type 2 iodothyronin deiodinase transgene expression in the mouse heart causes cardiac-specific thyrotoxicosis.
• The role of selenocysteine 133 in catalysis by the human type 2 iodothyronine deiodinase.
• Usefulness of ultrasonography in the management of nodular thyroid disease.
• Selective proteolysis of human type 2 deiodinase: a novel ubiquitin-proteasomal mediated mechanism for regulation of hormone activation.
• Distinct subcellular localization of transiently expressed types 1 and 2 iodothyronine deiodinases as determined by immunofluorescence confocal microscopy.
• Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas.
• Substrate-induced down-regulation of human type 2 deiodinase (hD2) is mediated through proteasomal degradation and requires interaction with the enzyme's active center.
• Characterization of the 5'-flanking and 5'-untranslated regions of the cyclic adenosine 3',5'-monophosphate-responsive human type 2 iodothyronine deiodinase gene.
• Thyroid hormone regulates hyperpolarization-activated cyclic nucleotide-gated channel (HCN2) mRNA in the rat heart.
• Cloning and expression of the chicken type 2 iodothyronine 5'-deiodinase.
• Regional expression of the type 3 iodothyronine deiodinase messenger ribonucleic acid in the rat central nervous system and its regulation by thyroid hormone.
• The 3'-untranslated region of human type 2 iodothyronine deiodinase mRNA contains a functional selenocysteine insertion sequence element.
• Studies of the hormonal regulation of type 2 5'-iodothyronine deiodinase messenger ribonucleic acid in pituitary tumor cells using semiquantitative reverse transcripti...
• Type 2 iodothyronine deiodinase in rat pituitary tumor cells is inactivated in proteasomes.
• The guanosine monophosphate reductase gene is conserved in rats and its expression increases rapidly in brown adipose tissue during cold exposure.
• Further characterization of thyroid hormone response elements in the human type 1 iodothyronine deiodinase gene.
• The role of the active site cysteine in catalysis by type 1 iodothyronine deiodinase.
• Regional distribution of type 2 thyroxine deiodinase messenger ribonucleic acid in rat hypothalamus and pituitary and its regulation by thyroid hormone.
• Van Meter Prize of the American Thyroid Association to Gregory Brent.
• Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyronine deiodinases.
• Characterization of the promoter of the rat sarcoplasmic endoplasmic reticulum Ca2+-ATPase 1 gene and analysis of thyroid hormone responsiveness.
• Type 2 iodothyronine deiodinase is highly expressed in human thyroid.
• Molecular biological and biochemical characterization of the human type 2 selenodeiodinase.
• In vivo genomic footprinting of thyroid hormone-responsive genes in pituitary tumor cell lines.
• Is there a negative TRE in the luciferase reporter cDNA?
• Mammalian type 2 deiodinase sequences: finally, the end of the beginning.
• Structural features of thyroid hormone response elements that increase susceptibility to inhibition by an RTH mutant thyroid hormone receptor.
• The structure of the coding and 5'-flanking region of the type 1 iodothyronine deiodinase (dio1) gene is normal in a patient with suspected congenital dio1 deficiency.
• Enhancement of thyroid hormone receptor isoform specificity by insertion of a distant half-site into a thyroid hormone response element.
• Effect of 3,5,3'-Triiodothyronine (T3) administration on dio1 gene expression and T3 metabolism in normal and type 1 deiodinase-deficient mice.
• Type 3 lodothyronine deiodinase: cloning, in vitro expression, and functional analysis of the placental selenoenzyme.
• A novel retinoid X receptor-independent thyroid hormone response element is present in the human type 1 deiodinase gene.
• Structural and functional differences in the dio1 gene in mice with inherited type 1 deiodinase deficiency.
• Topological analysis of the integral membrane protein, type 1 iodothyronine deiodinase (D1).
• Pituitary cells respond to thyroid hormone by discrete, gene-specific pathways.
• Prospective studies of thyroid function in patients receiving gold therapy.
• The American Thyroid Association: d'où venons nous? Que sommes nous? Où allons nous? (Whence do we come? What are we? Where are we going?).
• Nutritional and hormonal regulation of thyroid hormone deiodinases.

Schools

---

• Columbia University College Of Physicians and Surgeons

• Colum Presby Hospital

• Cincinnati Genl Hospital

Doctors Specialties

---

• Internal Medicine
• Endocrinology

Accepted Insurances

---

Awards

---

• Elected Member

Education

---

• University Hospital - University of Cincinnati College of Medicine
• New York Presbyterian Hospital - Columbia Campus
• Columbia University College of Physicians & Surgeons

Hospital

---

• Dana-Farber Cancer Institute
• Brigham and Women's Hospital

Drug Facts

---

NPI NUMBER		1700842952
NPPES Provider LastName		LARSEN
NPPES Provider FirstName		P
NPPES Provider ZIPCode		02115
NPPES Provider State		MA
Specialty Description		Endocrinology
Total Claim Count		128.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1700842952
Last Name Of The Provider	LARSEN
First Name Of The Provider	P
View All

Similar Doctors

---

	Dr. Le Min, MD This Doctor is OpenDoctor Recommended.
	Dr. Marie E. McDonnell, MD This Doctor is OpenDoctor Recommended.
	Dr. Emma B. Morton-Eggleston, MD
	Adil H. Khan, MB BS This Doctor is OpenDoctor Recommended.
	Dr. Claudia E. Paba, MD This Doctor is OpenDoctor Recommended.
	Dr. Lauren B. Doctoroff, MD This Doctor is OpenDoctor Recommended.
	Dr. Diane E. Krause, MD This Doctor is OpenDoctor Recommended.
	Dr. Rebecca P. Gelber, MD
	Dr. Deborah Blazey-Martin, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog